SEC Form 3 · accession 0001817449-26-000007
Electra Therapeutics, Inc. · ETRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy Stagliano
Director
Period of report
Sep 18, 2026
Accepted (ET)
Sep 18, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002088082
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2,F1 | $5.23 | holding | — | — | — | — | Mar 23, 2032 | Common Stock | 94,538 | — | I |
| Director Stock Option(right to buy)F3 | $4.96 | holding | — | — | — | — | Feb 12, 2036 | Common Stock | 288,814 | — | D |
| Director Stock Option (right to buy)F4 | $15.00 | holding | — | — | — | — | Sep 16, 2036 | Common Stock | 68,819 | — | D |
| Series A Convertible Preferred StockF5 | — | holding | — | — | — | — | — | Common Stock | 255,635 | — | D |
Explanation of responses
- F1The shares subject to this option are fully vested.
- F2The Reporting Person is trustee of the trust.
- F31/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F4The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.
- F5Each share of Series A Convertible Preferred Stock (the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.